Clinical effect of Argatroban combined with Urinary Kallindinogenase in the treatment of acute cerebral infarction
HU Ying1SU Jing
1.Department of Internal Medicine-Neurology，Liaoyu Hospital of Dalian City，Liaoning Province，Dalian 116033，China;
2.Department of Internal Medicine-Neurology，the Second Hospital Affiliated of Dalian Medical University，Liaoning Province，Dalian 116027，China
Abstract：Objective To explore the clinical effect of Agathorban combined with Urinary Kallindinogenase in the treatment of acute cerebral infarction.Methods A total of 86 patients with acute cerebral infarction treated in Liaoyu Hospital of Dalian City in Liaoning Province for 4.5 to 48.0 hours from April 2014 to June 2016 were selected as the study subjects，they were divided into control group （43 cases）and treatment group （43 cases）according to random number table method，the control group was given Aspirin+Clopidogrel Dual Anti-platelet aggregation and routine treatment，the treatment group received intravenous administration of thrombin inhibitor Agathorban+Proteolytic Enzyme Urinary Kallindinogenase and routine treatment，blood routine and coagulation index activated partial thromboplastin time （APTT）were monitored in both groups during treatment.NIHSS and modified Rankin scale （mRS）were used to evaluate the degree of neurological impairment before treatment and 10 days after treatment，and the safety of medication was also evaluated.Results The scores of NIHSS and mRS in the treatment group were lower than those in the control group after treatment，the differences were statistically significant （P＜0.05）.The total effective rate of the treatment group was higher than that of the control group，the difference was significant（P＜0.05）.There were no significant differences in leucocyte and platelet levels between the two groups （P＞0.05）.The APTT of the treatment group was longer than that of the control group after treatment，the difference was significant （P＜0.05）.There were no gingival bleeding，blood in sputum，hematuria，hematemesis，tarry stool，or mild injury with long-term hemorrhage and coagulation in both groups.Conclusion In the routine treatment of acute cerebral infarction，the combined use of Agartraban and Urekrin is superior to Aspirin and Clopidogrel in dual anti-platelet aggregation plus routine treatment，which can significantly reduce scores of NIHSS and mRS，improve the degree of neurological recovery，and medication is safe.
胡英;苏静. 阿加曲班联合尤瑞克林治疗急性脑梗死的临床效果[J]. 中国当代医药, 2019, 26(4): 103-106.
HU Ying1SU Jing. Clinical effect of Argatroban combined with Urinary Kallindinogenase in the treatment of acute cerebral infarction. 中国当代医药, 2019, 26(4): 103-106.
京公网安备 11010502046607号